- Home
- IMRX vs HERE Comparison
IMRX vs HERE Comparison
Compare IMRX & HERE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$4.93
N/A
Current Price
$4.08
Company Overview
Basic Information| Metric | IMRX | HERE |
|---|---|---|
| Founded | 2008 | 2019 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Consumer Services |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 366.1M | 296.4M |
| IPO Year | 2021 | 2023 |
Fundamental Metrics
Financial Performance| Metric | IMRX | HERE |
|---|---|---|
| Price | $4.93 | $4.08 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $17.20 | N/A |
| AVG Volume (30 Days) | ★ 1.2M | 162.7K |
| Earning Date | 03-19-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 43.17 |
| EPS | N/A | ★ 1.45 |
| Revenue | N/A | ★ $286,877,037.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $47.96 |
| P/E Ratio | ★ N/A | $6.33 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.10 | $2.15 |
| 52 Week High | $10.08 | $15.64 |
Technical Indicators
Market Signals| Indicator | IMRX | HERE |
|---|---|---|
| Relative Strength Index (RSI) | 47.13 | 29.79 |
| Support Level | $4.86 | $3.82 |
| Resistance Level | $5.15 | $4.80 |
| Average True Range (ATR) | 0.31 | 0.24 |
| MACD | 0.07 | -0.08 |
| Stochastic Oscillator | 60.98 | 13.01 |
Price Performance
Historical Comparison IMRX
HERE
About IMRX Immuneering Corporation
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.